Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Launches Early Access Program for SNP Genotyping Platform

NEW YORK (GenomeWeb) — Fluidigm said today that it has launched an early access program for its new SNP genotyping platform, the Juno system, for its key production genomics customers and prospects.

Juno is a sample prep engine for SNP genotyping that allows scientists to genotype low-concentration DNA samples from tissue, buccal swabs, formalin-fixed paraffin-embedded samples, and polyploidy organisms in less than three hours, Fluidigm said.

Traditionally, SNP genotyping requires high-concentration and -quality samples, and substantial amounts of reagents, resulting in high operating costs, the company added. These requirements have hampered the practical use of low-concentration DNA samples, such as buccal swabs and FFPE, in production genomics.

The Juno system uses an integrated fluidic circuit that incorporates pre-amplification and genotyping of up to 96 samples and 96 assays on a single chip. The system also requires as little as 5.5 nanograms of DNA at a concentration of 2.5 nanograms per microliter of sample, the company said.

Fluidigm is also releasing new master mix chemistries that combine all of the reagents need to perform integrated genotyping on the Juno system.

Targeted uses for the Juno system include sample identification, quality control, and DNA fingerprinting by biobanking and cell culture facilities, and integrated on-chip pre-amplification and genotyping analysis by Ag-Bio customers, Fluidigm said.

"Our production genomics customers commonly struggle with highly variable or low-concentration samples, whether they come from a buccal swab, a needle biopsy, a seed, or a biobank. Juno is an answer to this challenge," CEO Gajus Worthington said in a statement.

The company hasn't yet named any participants in the early access program for the Juno system.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more